ID: MRFR/Pharma/0595-HCR | February 2021 | Region: Global | 110 pages
Live Attenuated Vaccines Market Scenario
Vaccines created by reducing the virulence of pathogens are known as Live Attenuated Vaccines (LAV). These pathogens are weakened under laboratory conditions. The vaccine triggers a potent immune response against infectious diseases. They initiate memory cell production in order to respond to the pathogen that previously invaded the body. Increasing awareness about vaccination, growing government funding for vaccination programs and increasing prevalence of infectious diseases drive the growth of live attenuated vaccines market. Improving healthcare infrastructure, increasing demand for LAV, and emphasis on prevention of diseases also drives this market. live attenuated vaccines market is expected to reach USD 45.2 billion in 2023 from USD 34.2 billion in 2016 with a CAGR of approximately 10.7% during the forecast period 2017-2023.
The main objective of this research is to provide information about live attenuated vaccines market, types of vaccine, vaccine development, and its end users.
Source: Press release, company presentation, annual reports
GlaxoSmithKline, plc. (U.K.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), MedImmune, LLC (U.S.), Sanofi (France), and Serum Institute of India Pvt. Ltd. (India).
Live attenuated vaccines market is segmented on the basis of type, which includes bacterial and viral vaccines. Bacterial vaccines includes BCG vaccine, and viral vaccine include oral polio vaccine (OPV), measles, rotavirus, and yellow fewer & other viral vaccines. On the basis of vaccine development, the live attenuated vaccines market is segmented into tissue culture, embryonated eggs, live animals, and on the basis of end users, it is sub-segmented into hospitals, clinics, diagnostic centers, research institute & others.
Sources: Press release, presentation, company website, annual reports, government records, journals expert interview.
Globally, live attenuated vaccines market consists of four regions America, Europe, Asia Pacific and the Middle East & Africa. North America is the largest market in the world. Initiatives taken by the government for vaccination against diseases like influenza, as well as excellent management of public awareness programs are boosting the growth of this market in North America. Europe is the second largest market owing to availability of funds for R&D activities and growing emphasis on R&D. Asia Pacific shows the fastest growth in this market due to an increase in prevalence of communicable diseases. India is expected to be an emerging and the fastest growing market. The live attenuated vaccines market shows steady growth in the Middle East & Africa.
The report for live attenuated vaccines market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the live attenuated vaccines market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Vaccine Development, End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||GlaxoSmithKline, plc. (U.K.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), MedImmune, LLC (U.S.), Sanofi (France), and Serum Institute of India Pvt. Ltd. (India)|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Live Attenuated Vaccines Market size can inflate to USD 45.2 billion by 2023.
Live Attenuated Vaccines Market was worth USD 34.2 billion in 2016.
Live Attenuated Vaccines Market is expected to expand at 10.7% CAGR from 2017 to 2023.
North America is expected to dominate the Live Attenuated Vaccines Market till 2023.
Merck & Co., Astellas Pharma Inc., Sanofi, GlaxoSmithKline, plc., Emergent BioSolutions, Inc., MedImmune, LLC, Serum Institute of India Pvt. Ltd., Pfizer, Inc., Johnson & Johnson, and CSL Limited are major players of the Global Live Attenuated Vaccines Market.